On Tuesday, Johnson & Johnson (NYSE:JNJ) will release its quarterly report, and investors have to be pleased with the health-care conglomerate's ability to keep moving its earnings and revenue in the right direction. Even as drug manufacturers Pfizer (NYSE:PFE) and Merck (NYSE:MRK) face the prospect of falling revenue this year, Johnson & Johnson has been able to use its triple attack of pharmaceuticals, over-the-counter consumer products, and medical devices to find ways to keep growing.

Johnson & Johnson is a ubiquitous company, with products that people around the world know almost from birth. Yet even though products like its baby shampoos and Band-Aid bandages might be the most familiar things J&J offers, the real growth story for Johnson & Johnson lately has come from its pharmaceutical division. Can the health-care giant manage to keep finding new ways to bolster its growth even as many investors start to look more critically at health care-related stocks? Let's take an early look at what's been happening with Johnson & Johnson over the past quarter and what we're likely to see in its report.

Stats on Johnson & Johnson

Analyst EPS Estimate


Change From Year-Ago EPS


Revenue Estimate

$18.00 billion

Change From Year-Ago Revenue


Earnings Beats in Past 4 Quarters


Source: Yahoo! Finance.

Will Johnson & Johnson earnings give investors another boost?
Analysts have been just a little bit downbeat about Johnson & Johnson earnings in recent months. They've left their first-quarter estimates unchanged, but they've nicked off $0.03 per share -- or about half a percent -- from their full-year 2014 projections. That hasn't held the stock back, though, with shares gaining almost 4% since early January.

Johnson & Johnson's fourth-quarter report showed just how important pharmaceuticals have become to the company's overall success. Making up nearly 40% of sales last year, the pharma segment saw substantial growth both from its key Remicade rheumatoid arthritis drug and newer treatments such as prostate cancer-treating Zytiga and psoriasis fighter Stelara. By contrast, though, medical-device sales struggled, and the consumer-products division also failed to see the level of growth that investors had expected.

One problem Johnson & Johnson has faced is that hospitals and other health-care professionals aren't certain enough about the future prospects for their business to make immense capital investments in J&J medical device products. Once the Affordable Care Act fully plays out and once health-care providers can wrap their heads around future business opportunities in the industry, Johnson & Johnson could see its medical device business start getting traction again.

Yet the collapse of biotech stocks could actually refocus investor attention on Johnson & Johnson. Many players in biotech are highly speculative, living or dying by the clinical trial results that they're able to produce. By contrast, Johnson & Johnson has had great success with its pharma pipeline, while largely avoiding the extent of the patent-cliff issues that drove sales at Pfizer, Merck, and other pharma rivals sharply lower. In the long run, Johnson & Johnson will have its own patent challenges, but for now, the defensive characteristics that Johnson & Johnson stock offers investors looks highly attractive in light of the stock market's volatility so far in 2014.

In the Johnson & Johnson earnings report, watch to see whether the pharma side of the business continues to shine. Although good news from pharmaceuticals is always welcome, Johnson & Johnson will eventually have to start firing on all three cylinders in order to reach its full potential.

Click here to add Johnson & Johnson to My Watchlist, which can find all of our Foolish analysis on it and all your other stocks.

Dan Caplinger has no position in any stocks mentioned. The Motley Fool recommends and owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.